Why did Flanders say goodbye to Michiel Vandeweert inside KRC Genk’s stadium?

Hundreds of relatives, friends, football supporters and other mourners gathered at KRC Genk’s Cegeka Arena on Monday, 17 August, to say goodbye to Michiel Vandeweert, who died aged 28 after living nearly twice as long as the 14.5-year untreated average associated with progeria. Flemish newspapers reporting from Genk described a long queue outside the stadium and the arrival of motorcyclists who had come to honour him. The ceremony concluded a public farewell built around the club Vandeweert had supported throughout his life.

The location was not ceremonial decoration. KRC Genk was part of Vandeweert’s identity, and the club had already remembered him before its first home match following his death. Supporters raised a large tifo in his honour, turning the stadium’s familiar match-day language into an expression of grief. Hosting the funeral on the pitch carried that gesture further: a professional football venue became, for several hours, a civic meeting place for Limburg and the wider Flemish public.

Vandeweert, from Diepenbeek, had Hutchinson-Gilford progeria syndrome, an exceptionally rare genetic condition that causes severe premature ageing. The European Medicines Agency says it occurs in roughly one in four million births and is especially dangerous because it produces accelerated cardiovascular disease. Intelligence is not impaired. Most patients appear healthy at birth before growth problems and other physical signs emerge during early childhood.

He was diagnosed at five, according to material published by the Progeria Research Foundation. He later took part in the foundation’s first clinical trial in 2007 and used lonafarnib daily, alongside regular physiotherapy. His participation made him more than a visible patient: he was one of the small number of people whose experience helped researchers assess a treatment for a disease for which conventional large clinical trials are impossible.

That distinction matters. Vandeweert became widely known in Flanders through television appearances, social media, gaming streams, a book and public speaking, but he repeatedly presented himself as a person with ordinary interests rather than as a diagnosis. In a 2019 foundation interview, he said he wanted people to understand that looking different did not mean being different. His public life helped give an ultra-rare condition a recognisable human face without reducing his own identity to medical adversity.

Shortly before his death, he and his sister Amber, who also has progeria, appeared in the two-part documentary series “How to be alive: Amber en Michiel”. Production information described the project as a portrait of time, ambition and daily life rather than a conventional illness documentary. The timing gave the programme an unforeseen finality, but its underlying purpose remains important: it allowed the siblings to shape how their lives were represented.

The medical background has changed substantially during Vandeweert’s lifetime. The European Union authorised Zokinvy, the brand name for lonafarnib, in July 2022 for genetically confirmed progeria and related laminopathies in patients aged at least 12 months. The EMA’s latest overview says treated patients in the available long-term comparison lived an average of 4.3 years longer than untreated patients, although limited evidence means the benefit could be as low as 2.6 years. The medicine remains subject to additional monitoring and annual review because the patient population is so small.

This is also where the story touches the economics of rare-disease care. A medicine can receive a single EU-wide marketing authorisation, but the EMA notes that pricing and reimbursement decisions remain national. For Belgian families affected by an ultra-rare disorder, the practical questions therefore concern access to specialist doctors, physiotherapy, genetic testing, cross-border expertise and reimbursement—not simply whether a therapy exists. The company marketing Zokinvy, TMC Pharma (EU) Limited, must continue supplying registry data on safety, effectiveness and quality of life under the medicine’s exceptional authorisation.

The wider market is structurally difficult. The Progeria Research Foundation currently counts 223 identified people living with progeria or related laminopathies across 55 countries. Such tiny populations offer little prospect of recovering conventional development costs through volume, which is why EU orphan-drug incentives, international patient registries and philanthropic research networks matter. Vandeweert’s own treatment history illustrates how patients, families, researchers and pharmaceutical companies depend on one another when evidence must be built from only dozens of cases.

KRC Genk’s role reveals another kind of institution. The club is a professional sports business with ticketing, sponsorship, hospitality and a stadium carrying technology company Cegeka’s name. Yet it also operates as social infrastructure in a former mining region where football provides a shared identity across generations and communities. KRC Genk says its permanent memorial wall for deceased supporters has existed for ten years, reflecting the club’s deliberate effort to remain connected to supporters beyond commercial transactions and match results.

There is no meaningful financial consequence from Monday’s ceremony for ordinary Belgian households. Its practical importance lies elsewhere: it shows families confronting rare disease that public institutions and businesses can make room for grief, while reminding policymakers that medicines alone do not constitute care. Treatment must sit alongside rehabilitation, psychosocial support and a system capable of coordinating expertise across borders.

The farewell now gives way to quieter responsibilities. Vandeweert’s family and friends will grieve outside the public gaze; KRC Genk will carry his memory within its supporter culture; and researchers will continue working with the exceptionally limited evidence available. No cure currently exists. The next measurable developments will come through the EU-required patient registry, further evaluation of lonafarnib and experimental approaches such as gene-based therapies. Monday’s ceremony could not resolve those uncertainties. It did, however, return Vandeweert to the place where many people knew him best: not as a medical case, but as a Genkie.